Tenders Are Invited For Antivirals For Systemic Use - Delivery Of Medicinal Products For 2025, Granted In Accordance With Ordinance No. 34 Of 25.11.2005 For The Order For Payment From The Hold. Budget For The Treatment Of Bulgarian. Call. For Diseases, Outside The Scope Of Obligation, For The Treatment Of Patients With Hiv/Aids, Tuberculosis, Psycho. And Behavioral Disorders Due To The Use Of Opioids, Addiction Syndrome - Emtricitabine/Tenofovir Disorroxil

Antivirals For Systemic Use - Delivery Of Medicinal Products For 2025, Granted In Accordance With Ordinance No. 34 Of 25.11.2005 For The Order For Payment From The Hold. Budget For The Treatment Of Bulgarian. Call. For Diseases, Outside The Scope Of Obligation, For The Treatment Of Patients With Hiv/Aids, Tuberculosis, Psycho. And Behavioral Disorders Due To The Use Of Opioids, Addiction Syndrome - Emtricitabine/Tenofovir Disorroxil. “Delivery Of Medicinal Products For 2025, Granted Pursuant To Ordinance No. 34 Of 25.11.2005 On The Order For Payment By The State Budget Of Treatment Of Bulgarian Citizens For Diseases, Outside The Scope Of Compulsory Health Insurance, For The Treatment Of Patients With Hiv/Aids, Emtricitabine/ Tenofovir Disoproxil With Decision No. F631841/ 31.03.2025. The Ministry Of Health Has Opened A Procedure With The Subject:“ Delivery Of Medicinal Products For 2025, Granted In Accordance With Ordinance No. 34 Of 25.11.2005 For The Payment Order From The State Budget Provision, For The Treatment Of Patients With Hiv/Aids, Tuberculosis, Mental And Behavioral Disorders Due To The Use Of Opioids, Dependence Syndrome, Including 23 (Twenty-Three) Self-Separate Positions (00080-2025-0006). On The Grounds Of Art. 110, Para. 1, Item 1 Of The Public Procurement Act, Due To The Lack Of Tenders Submitted, The Procedure Was Terminated In Lot No 8 Emtricitabine/Tenofovir Disoproxil. The Antiretroviral Medicinal Product Emtricitabine/Tenofovir Disoproxil In The Termination Position Is Required For The Therapeutic Regimens Of The Patients Prescribed Because Of Its Specific Therapeutic Indications And Pharmacological Characteristics. In 2025, For The Treatment Of Emtricitabine/Tenofovir Disoproxil, 603 Patients Were Provided, Respectively 7 236 Packs (217 080 Tablets).